ClinicalTrials.gg
Active, not recruitingNCT04486378Updated Oct 7, 2026

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

A Phase 2 interventional study of RO7198457 intravenous (IV) and Observational group (no intervention) in Colorectal Cancer Stage II and Colorectal Cancer Stage III, sponsored by BioNTech SE. Active, not recruiting at 85 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by BioNTech SE · Phase 2, Interventional, and Treatment

Updated Oct 7, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
327
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 461 studies in Colorectal Neoplasms with a site in Spain — 96 open to participants now, 149 under way, 18 of them phase 3. Colorectal Neoplasms · Spain.

Planned enrollment
125th of 404
327 · median 168
Started
2021
with 39 others
Phase 2
119 of 461
14 open now
Primary completion
2026-11
later than 42 of 148 live
Registered
267th of 461
by date

Among the 461 studies in Colorectal Neoplasms with a site in Spain, this one is the 125th largest by planned enrollment of the 404 interventional ones that give a count, is one of 40 that started in 2021, is one of 119 in phase 2, reaches primary completion later than 42 of the 148 other live ones, and was the 267th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

96 of the 461 studies in Colorectal Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

91 more — sign in →

All 96 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 461 studies in Colorectal Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.

Read the detailed description

Patients will receive up to 15 doses of RO7198457 over the course of trial treatment.

03

Conditions studied

  • Colorectal Cancer Stage II
  • Colorectal Cancer Stage III

Keywords

  • Cancer
  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be a man or woman of at least 18 years of age.
  • Patients must have Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III colon cancer per American Joint Committee on Cancer (AJCC) 2017 that has been surgically totally resected (R0 confirmed by pathology report). Stage II (high risk) colon cancer is defined as Stage II disease with any of the following risk factors for recurrence:

    • T4
    • Grade ≥ 3.
    • Clinical presentation with bowel obstruction or perforation.
    • Histological signs of vascular, lymphatic or perineural invasion.
    • \< 12 nodes evaluated after surgery.

      • For the CLM Cohort: patients must have colorectal cancer (mCRC) (Stage IV) with resected CLM (synchronous and metachronous CLM within 6 months of initial diagnosis) per AJCC 2017, after standard of care (SoC) primary resection and curative-intent hepatectomy (R0 confirmed by pathology report) with or without (neo-) chemotherapy (prior to hepatectomy), and planned adjuvant chemotherapy.
      • For the Biomarker Cohort: patients with tumors of the colon, including but not limited to, colon adenocarcinoma, carcinoid tumors (including goblet cell carcinoid/adenocarcinoma), and tumors of the appendix, whose tumors were surgically resected and are planned for adjuvant chemotherapy (per institutional standards), can be included.
  • Patients must have detectable ctDNA prior to start of adjuvant chemotherapy (AdCTx) (except for the Biomarker Cohort).

    • ctDNA assay must be performed through this trial or study BNT000-001 ctDNA screening protocol.
  • Patients must have an Performance Status of 0-1.
  • Patients must have adequate hematologic, bone marrow and organ function as defined by the protocol.
  • Adequate tumor material in formalin-fixed paraffin embedded blocks or as sectioned tissue (only upon approval by sponsor) must be available (as described in the laboratory manual). For the CLM Cohort: tumor material must come from primary resection for patients who undergo staged approach, or from available archival material from the previously untreated tumor from the primary.
  • At least 5 tumor neoantigens identified in the provided tumor sample.
  • The patient has started a standard of care AdCTx preferably within 8 weeks but no later than 10 weeks post-surgery and has completed at least 3 months of treatment of a 3- or a 6-month course of chemotherapy (including rest days). For the CLM Cohort: patient must have completed AdCTx with or without (neo-)adjuvant chemotherapy for up to 6 months in total or total intended amount determined by care providers per SoC. AdCTx must have started preferably within 8 weeks, but no later than 10 weeks, after hepatectomy. For the Biomarker Cohort: patient must have received at least one cycle of adjuvant chemotherapy per institutional standards.

Exclusion criteria

Exclusion Criteria:

  • Patients with uncontrolled intercurrent illness as defined by the protocol.
  • Diagnosed microsatellite instability high tumors.
  • Prior therapy with any of the following:

    • (radio)chemotherapy prior to surgery.
    • Treatment with systemic medication within 2 weeks prior to initiation of trial treatment or anticipation of need for systemic immunosuppressive medication during trial treatment, with the exception of low dose defined as 10 mg oral prednisone (or equivalent).
    • Current or recent (within the 28 days prior to randomization) treatment with another drug.

      • Exception for the CLM Cohort: primary tumor must be resected and (neo-)adjuvant chemotherapy prior to curative-intent hepatectomy is accepted.
  • Toxicities from previous anti-cancer therapies that have not resolved to baseline levels or to Grade 1 or less except for alopecia and peripheral neuropathy.
  • Patients who developed disease during screening/receiving standard of care treatment (not applicable for the Exploratory Cohort or the Biomarker Cohort).
  • Patients with known past or current other than inclusion diagnosis, except for:

    • Cervical carcinoma of Stage 1B or less.
    • Non-invasive basal cell or squamous cell skin carcinoma.
    • Non-invasive, superficial bladder cancer.
    • Prostate cancer with a current prostate-specific antigen level \< 0.1 ng/mL.
    • Any curable cancer with a complete response of > 2 years duration.
  • Patients with known allergies, , or intolerance to RO7198457 or its .
  • Patients who had major surgery (e.g., surgery requiring general anesthesia) within 4 weeks before screening, or will not have fully recovered from surgery, or have surgery planned during the time the patient are expected to participate in the trial.
  • Patients with positive serology for indicative of active hepatitis B infection:

    • Positive test for hepatitis B surface antigen (HBsAg) OR
    • Negative test for HBsAg AND positive test for antibodies to hepatitis B core antigens (anti-HBc) AND positive test for hepatitis B virus (HBV) DNA.

      • Serological markers indicative of vaccination (isolated antibodies to hepatitis B surface antigens [anti-HBs]) or resolved natural infection without viral load (anti-HBc with negative HBsAg and negative HBV DNA) are not exclusionary.
  • Active virus (HCV) infection; patients who have completed curative antiviral treatment with HCV viral load below the limit of quantification are allowed.
  • Patients who have a history of (HIV) antibody positivity, or tests positive for HIV at screening.
  • Patients who have had prior splenectomy.

NOTE: Other protocol defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
327 participants (estimated)

Study arms

  • Experimental
    RO7198457

    Participants will receive a recommended dose of RO7198457.

    Drug: RO7198457 intravenous (IV)

  • Other
    Observational Group

    Observational group will undergo watchful waiting, which is the standard of care in this setting.

    Other: Observational group (no intervention)

  • Experimental
    Biomarker Cohort

    Drug: RO7198457 intravenous (IV)

  • Experimental
    Exploratory Cohort

    Drug: RO7198457 intravenous (IV)

  • Experimental
    Colorectal Liver Metastasis (CLM) Cohort

    Drug: RO7198457 intravenous (IV)

Interventions

  • RO7198457 administered as an IV injection at protocol-specified intervals over 12 months.

  • OtherObservational group (no intervention)

    watchful waiting

06

What researchers measure

Primary outcomes

  1. Disease-free survival (DFS)

    DFS defined as the time from randomization to occurrence of any of the following events, whichever occurs first: * Locoregional recurrence or distant metastases as determined by an independent central radiology assessment. * Occurrence of second primary (same or other) cancer as determined by an independent central radiology assessment. * Death from any cause. * Loss to follow-up is censored.

    Time frame: Through study completion, up to 5 years

Secondary outcomes

  1. Relapse-free survival (RFS)

    RFS is defined as the time from randomization to occurrence of any of the following events, whichever occurs first: * Locoregional recurrence or distant metastases as determined by the investigator. * Death from any cause. * Occurrence of second primary (same or other) cancer as determined by the investigator is ignored. * Loss to follow-up is censored.

    Time frame: Through study completion, up to 5 years

  2. Time to recurrence (TTR)

    TTR is defined as the time from randomization to occurrence of any of the following events (i.e., events related to the same cancer), whichever occurs first: * Locoregional recurrence or distant metastases as determined by the investigator. * Death from same cancer. * Occurrence of second primary (same or other) cancer as determined by the investigator is ignored. * Loss to follow-up and deaths from other cancer, non-cancer-related deaths, treatment-related deaths are censored.

    Time frame: Through study completion, up to 5 years

  3. Time to treatment failure (TTF)

    TTF is defined as the time from randomization to occurrence of any of the following events, whichever occurs first: * Locoregional recurrence or distant metastases as determined by the investigator. * Occurrence of second primary (same or other) cancer as determined by the investigator. * Death from any cause except non-cancer related death. * Start of new cancer therapy. * Loss to follow-up and non-cancer-related deaths are censored.

    Time frame: Through study completion, up to 5 years

  4. Overall survival (OS)

    OS defined as the time from randomization to death from any cause.

    Time frame: Through study completion, up to 5 years

  5. Change of ctDNA status (approximately every 3 months)

    Time frame: Through study completion, up to 5 years

  6. Occurrence of treatment emergent adverse event (TEAE)

    TEAE, including Grade 3+, serious, fatal TEAE by relationship (adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0).

    Time frame: 15 months

  7. Occurrence of dose reduction and discontinuation of RO7198457 due to a TEAE.

    Time frame: 15 months

07

Study locations

85 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Nov 2026, 68 months after the start.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's planned 68 months is above that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

Completion moved once since we started tracking on Sep 25, 2026: Aug 2030 → Nov 2026, on Oct 7, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2020
First posted
Jul 24, 2020
StartActual
Mar 8, 2021
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026was Aug 2030
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Aug 2030→Nov 2026
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Study completion Aug 2030→Nov 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04486378
Lead sponsor
BioNTech SE
Collaborators
Genentech, Inc.
Responsible party
Sponsor
First posted
Jul 24, 2020
Start date
Mar 8, 2021
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Oct 7, 2026

Study contacts

BioNTech Responsible Person
study director · BioNTech SE

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autogene cevumeran

Start the discussion